Literature DB >> 33252357

Pheochromocytoma/paraganglioma preclinical models: which to use and why?

Serena Martinelli1, Mario Maggi1, Elena Rapizzi2.   

Abstract

Pheochromocytomas/paragangliomas (PPGLs) are rare neuroendocrine tumours linked to more than 15 susceptibility genes. PPGLs present with very different genotype/phenotype correlations. Certainly, depending on the mutated gene, and the activated intracellular signalling pathways, as well as their metastatic potential, each tumour is immensely different. One of the major challenges in in vitro research, whatever the study field, is to choose the best cellular model for that study. Unfortunately, most of the time there is not 'a best' cell model. Thus, in order to avoid observations that could be related to and/or dependent on a specific cell line, researchers often perform the same experiments using different cell lines simultaneously. The situation is even more complicated when there are only very few cell models obtained in different species for a disease. This is the case for PPGLs. In this review, we will describe the characteristics of the different cell lines and of mouse models, trying to understand if there is one that is more appropriate to use, depending on which aspect of the tumours one is trying to investigate.

Entities:  

Keywords:  animal models; cell models; pheochromocytoma/paraganglioma

Year:  2020        PMID: 33252357     DOI: 10.1530/EC-20-0472

Source DB:  PubMed          Journal:  Endocr Connect        ISSN: 2049-3614            Impact factor:   3.335


  6 in total

1.  Emerging considerations on mitochondrial and cytosolic metabolic features in SDH-deficient cancer cells.

Authors:  Joseph Vamecq; Pascal Pigny
Journal:  Mol Genet Metab Rep       Date:  2021-02-02

2.  Succinate Mediates Tumorigenic Effects via Succinate Receptor 1: Potential for New Targeted Treatment Strategies in Succinate Dehydrogenase Deficient Paragangliomas.

Authors:  Dieter M Matlac; Katerina Hadrava Vanova; Nicole Bechmann; Susan Richter; Julica Folberth; Hans K Ghayee; Guang-Bo Ge; Luma Abunimer; Robert Wesley; Redouane Aherrahrou; Margo Dona; Ángel M Martínez-Montes; Bruna Calsina; Maria J Merino; Markus Schwaninger; Peter M T Deen; Zhengping Zhuang; Jiri Neuzil; Karel Pacak; Hendrik Lehnert; Stephanie M J Fliedner
Journal:  Front Endocrinol (Lausanne)       Date:  2021-03-12       Impact factor: 5.555

3.  Treatment of Pheochromocytoma Cells with Recurrent Cycles of Hypoxia: A New Pseudohypoxic In Vitro Model.

Authors:  Jana Helm; Stephan Drukewitz; Isabel Poser; Susan Richter; Markus Friedemann; Doreen William; Hermine Mohr; Svenja Nölting; Mercedes Robledo; Stefan R Bornstein; Graeme Eisenhofer; Nicole Bechmann
Journal:  Cells       Date:  2022-02-05       Impact factor: 6.600

4.  Metformin Treatment Induces Different Response in Pheochromocytoma/Paraganglioma Tumour Cells and in Primary Fibroblasts.

Authors:  Serena Martinelli; Francesca Amore; Tommaso Mello; Massimo Mannelli; Mario Maggi; Elena Rapizzi
Journal:  Cancers (Basel)       Date:  2022-07-17       Impact factor: 6.575

5.  Novel Germline PHD2 Variant in a Metastatic Pheochromocytoma and Chronic Myeloid Leukemia, but in the Absence of Polycythemia.

Authors:  Aldesia Provenzano; Massimiliano Chetta; Giuseppina De Filpo; Giulia Cantini; Andrea La Barbera; Gabriella Nesi; Raffaella Santi; Serena Martinelli; Elena Rapizzi; Michaela Luconi; Mario Maggi; Massimo Mannelli; Tonino Ercolino; Letizia Canu
Journal:  Medicina (Kaunas)       Date:  2022-08-17       Impact factor: 2.948

Review 6.  The Anticancer Potential of Maslinic Acid and Its Derivatives: A Review.

Authors:  Lei Yu; Xiaofang Xie; Xiaoyu Cao; Junren Chen; Guanru Chen; Yan Chen; Gangmin Li; Junyuan Qin; Fu Peng; Cheng Peng
Journal:  Drug Des Devel Ther       Date:  2021-09-09       Impact factor: 4.162

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.